Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...

Why does Sanofi want the Novavax COVID vaccine? The Novavax COVID-19 vaccine, which is called Nuvaxovid outside of the U.S., isn't like the mRNA vaccines from Moderna and Pfizer. Instead of goading ...

First, a quick summary of Novavax's story so far. The vaccine maker's shares soared early in the COVID-19 vaccine race, skyrocketing more than 2,000% in 2020 as investors bet on its vaccine candidate.

Amanda Blum is a freelancer who writes about smart home technology, gardening, and food preservation. Previously, Amanda has worked as a technology strategist specializing in problem solving and ...

Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.

Five years ago, Novavax (NASDAQ: NVAX) was a little-known clinical-stage biotech whose leading pipeline candidate was an influenza vaccine. Then came the pandemic. The company quickly grew in ...

The U.S. just approved the updated non-mRNA COVID-19 vaccine made by Novavax for use and millions of doses are already being distributed across the country. “Novavax’s authorization today means people ...

Activist investor Shah Capital, which owns 6.7% of Novavax's stock, has claimed that the vaccine developer has been “historically mismanaged” as the firm tries to install new members onto the ...

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

As Novavax emerges from its “transition year” in 2023, the vaccine maker is still raising concerns among Wall Street investors in early 2024. The company's loss per share of $1.44 exceeded analyst ...

Novavax managed to get OKs for its COVID-19 shot in the EU, the U.K., Australia and South Korea before finally securing a much-coveted emergency use nod in the U.S. in July 2022. (Diy13/iStock/Getty ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...